Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

The Surge in Diabetes Worldwide

By Drug Discovery Trends Editor | April 11, 2016

The number of adults with diabetes worldwide has quadrupled since 1980, with a majority of the disease burden in low and middle income countries.

As this chart depicts, many of the biggest increases in diabetes prevalence occurred in developing regions: the Middle East, North Africa, and Southeast Asia. In 2014, 422 million adults lived with diabetes, compared with 108 million in 1980, according to a recent global report from the World Health Organization. During this period, the disease also became more common among men than women.

Infographic: The Unrelenting Global March Of Diabetes | Statista

The report includes data from 751 studies totaling 4.4 million adults in different world regions. It estimates age-adjusted diabetes prevalence for 200 countries — which means the researchers adjusted the results to account for diabetes becoming more common as a person ages.

Since about 90 percent of cases of adult diabetes are type 2, this observed rise is probably due to increases in type 2 diabetes, the researchers concluded.

“An aging population, and rising levels of obesity, mean that the number of people with diabetes has increased dramatically over the past 35 years,” said Majid Ezzati, senior author from Imperial College London. “Rates of diabetes are rising quickly in China, India, and many other low and middle income countries, and if current trends continue, the probability of meeting the 2025 UN global target is virtually non-existent.”


Filed Under: Drug Discovery

 

Related Articles Read More >

S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
Drug companies sign “Most Favored Nation” deals, then raise prices anyway
New gonorrhea antibiotic could treat resistant infections
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE